Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib + Niraparib for Platinum-resistant Recurrent Ovarian Clear Cell Carcinoma (CC-ANNIE)
ChiCTR2100047345Phase 2Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib and niraparib in clear cell ovarian cancer, sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Carbohydrate antigen 125 (CA-125) level. Started Sep 2021; status: recruiting.
02
Drugs
anlotinibniraparib
03
Conditions
clear cell ovarian cancer
Beyond the preview
Go deeper on ChiCTR2100047345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047345.